An investment firm with offices in the US and UK is partnering with a research organization to raise a $150 million fund focused on Regenerative Medicine (RM). Within RM, 80% of the fund will be towards immunotherapies, cell and gene therapies while the remaining 20% of the fund will be towards enabling-technologies that move RM forward in commercialization and medicine. The firm is looking to build a portfolio of 10-15 early stage RM companies, investing up to $10 million per deal with an initial investment of $1-3 million. The firm prefers to lead investments, though is willing to co-invest. The partnership recently launched the building of cell manufacturing and process manufacturing facilities for GMP, process development, and vector manufacturing that will enable the optimized production of cell lines and tissues necessary for early clinical development of RM technologies. All companies the firm invests in will have the valuable opportunity and prioritized access to the facility in developing their technology. The firm invests globally in RM companies, particularly those RM companies open to leveraging the existing infrastructure local to the firm’s partner organization.

The firm focuses exclusively on regenerative medicine, including stem cells, cell therapies, immunotherapies, and tissue engineering. The firm is interested in RM therapeutics, and is actively looking at several immunotherapies, such as those involving T-cells, dendritic cells, and/or checkpoint inhibitors. The firm is open to any indication in the therapeutic and medical device space, as long as the underlying RM technology is robust, and has demonstrated efficacy that is not incremental, but rather a dramatic change in the way the disease is currently treated. The firm invests in early projects, primarily from the pre-clinical stage through Phase II.

The firm is looking for compelling RM technologies, and is prepared to build or augment the management team and/or board of a company, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate venture fund located in Europe has an evergreen structure that allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. The fund has an annual investment capacity of approximately €50m. Investments are typically around €10 million with reserves to follow, and the firm prefers to take above 10% ownership. The fund invests primarily in Europe and in the USA/Canada.

The fund invests exclusively in life sciences, focusing on pharmaceuticals. The firm typically prefers to invest at phase I/II but has also made investments at earlier phases of development. The firm is open to opportunities in all therapeutic areas and indications.

The fund is oriented towards opportunities in the US and Europe and will take the role of lead investor in Europe. In US the firm prefers to syndicate with well-established VC investors specialized in life sciences. The fund expects to be actively in communication with management and represented.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A privately funded investment firm based in Canada focuses on making direct investments in the following business sectors: medical technology, medical clinics, healthcare IT and healthcare real estate. In medtech, the firm seeks to invest in seed stage companies. The firm looks to partner and fund scientific founders to launch a new company and will primarily invest in the seed stage round. The firm typically allocates $100K-$200K, and will syndicate with other investors outside of their region (including Australia) to invest in larger rounds of $500K or more. The firm has physician, medical experience, particularly in the surgical field. The firm invests globally and is currently seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in medical devices and healthcare IT. The firm is opportunistic in terms of the class of device and indications, and has particular interest in surgical devices and tools. The firm is additionally interested in digital health. The firm prefers to invest in the pre-prototype stage and with particular preference to very early-stage preclinical technology.

The firm is seeking startups with a maximum $5M pre-money valuation and will invest in pre-revenue companies. The firm is very hands-on after an investment, opening up and bringing their network to their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A firm with investment teams in both Silicon Valley and Europe is currently investing out of their second fund, and looks to invest in early-stage life science companies crossing all sectors. The firm focuses on Seed, Series A and Series B investments. Investment is in the form of equity with the firm making roughly 3-5 new investments per year. The firm typically invests $500K – $5M per round (depending on the stage and needs of the company), and generally invests $10-$15M throughout the life of a company. The firm is very comfortable leading investment rounds, and focuses on companies in the US and Europe.

In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, tools and medical device sectors. The firm is opportunistic in terms of sub-sectors and indications. The firm looks for companies with proprietary technologies that allow them to address unmet needs in a unique and compelling manner. The firm is not interested in healthcare IT, healthcare services or software companies.

The firm invests in privately-held companies with passionate founders and/or a strong management team. The firm looks to take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Boston is currently investing from its third fund of $220 million closed in 2015. The firm typically is the lead and first institutional investor in early-stage companies in the enterprise information technology (IT) space, including healthcare IT. The firm’s equity investment size ranges from $2-5 million. The firm is most active on the US East Coast and would consider opportunities from across the US. The firm plans to make 5-7 new investments in the following year

Within healthcare IT, the firm is seeking systems, technologies, and services that support clinical delivery to improve outcomes and efficiency of clinical care. The firm is not interested in consumer-facing products, genomic analytics, or life sciences software. The firm is looking for innovations that have demonstrated product-market fit in the form of recurring monthly revenue of $30K or more. Pre-revenue companies may be considered if there is a strong fit with its investment thesis. When it comes to healthcare IT investments, the firm often syndicates with strategic co-investors who understand the risks in the healthcare system, such as healthcare providers and payers.

The firm is looking for competent and experienced management teams with sector expertise. The firm brings in real world experience, industry knowledge and networks, and company-building skills to its portfolio companies. The firm takes a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

One of Europe’s largest venture capital firms is investing in life science companies through several funds which target seed, venture and growth-stage investments in European, North American and Asian companies. The initial investment size via these funds ranges from € 500K- € 10M and is in the form of straight equity. The firm is capable of leading or co-investing in financing rounds, however they prefer to have a local investor lead U.S. deals, unless it is a later-stage round (i.e. B, C, etc.) and the prior round was led by a U.S. investor. The firm has much more flexibility for European-based companies, and typically leads these rounds. The firm is aiming to make at least 6 more investments in 2016, with the average investment being € 3- € 5 M.

The firm takes a true venture approach to investing and prioritizes breakthrough technologies with a strong IP position. The firm is very interested in microbiome technologies and food technologies, and strongly believes in technologies at the intersection of food and pharma/biotech. Microbiome therapeutics and platforms are the primary interest, and the firm is willing to invest as early as pre-clinical in this subsector. As for other therapeutics preferred phase of development, typically only pre-clinical investments are made into companies with a platform technology, who aren’t relying on one therapeutic asset. Medical technology and connected health companies are also evaluated whatever the stage of development.

The firm prefers to work with mature, experienced management teams, but has no strict restrictions and is open to working with all entrepreneurs. The firm will invest in pre-revenue as well as revenue-generating companies, with maximum revenues of € 50M.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A multinational pharmaceutical company headquartered Japan with a subsidiary based in the USA is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets. Sponsored research may also be considered.

The firm’s external R&D is focused on both neurodegerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is also interested in diabetes, immunology, and infectious diseases. The firm is seeking platform technology with new MOA such as gene therapy, stem cell therapy, and monoclonal antibody acting on new targets. The firm prefers early stage, pre-POC assets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com